Acute Coronary Syndrome (ACS) Drug Market Prospects 2011-2021
What are the commercial prospects for the pharmacological treatment of acute coronary syndrome? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in that industry and market.
Our report gives you revenue forecasts to 2021 for treating acute coronary syndrome (ACS). You will find market predictions at total world, submarket, product and national levels. We aim to save you time and aid your decisions through our research, analysis and discussions.
Our study covers ACS treatments, including those for unstable angina (UA) and acute myocardial infarction (AMI). You will see commercial prospects for platelet aggregation inhibitors, anticoagulant treatments, fibrinolytic agents and their subgroups to 2021.
You will see how drugs like Plavix, Effient/Efient, ReoPro, Integrilin, Aspirin Cardio, Lovenox, Angiomax/Angiox, Arixtra and Metalyse/TNKase will perform to 2021. Our report provides many revenue forecasts and discussions, giving answers you need.
In particular, we discuss the R&D pipeline. There are opportunities for original and generic drugs for treating acute coronary syndrome from 2011 onwards.
We help you to assess the ACS treatment industry and market's strengths, weaknesses, trends and revenue opportunities to 2021. You will see what the future holds.
Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Industry and market analysis to help your work - so you won't be left behind
Our report gives you revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from our survey. We include 78 tables and charts and a research interview (shown in the accompanying lists).
Acute Coronary Syndrome (ACS) Drug Market Prospects 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for cardiovascular drugs.
Order our report now to gain industry and market information you need
Our report can benefit everybody interested in the industry and market for treating acute coronary syndrome. We give predictions and answers you need. Don't miss out - please order our report now.
Our report gives you revenue forecasts to 2021 for treating acute coronary syndrome (ACS). You will find market predictions at total world, submarket, product and national levels. We aim to save you time and aid your decisions through our research, analysis and discussions.
Our study covers ACS treatments, including those for unstable angina (UA) and acute myocardial infarction (AMI). You will see commercial prospects for platelet aggregation inhibitors, anticoagulant treatments, fibrinolytic agents and their subgroups to 2021.
You will see how drugs like Plavix, Effient/Efient, ReoPro, Integrilin, Aspirin Cardio, Lovenox, Angiomax/Angiox, Arixtra and Metalyse/TNKase will perform to 2021. Our report provides many revenue forecasts and discussions, giving answers you need.
In particular, we discuss the R&D pipeline. There are opportunities for original and generic drugs for treating acute coronary syndrome from 2011 onwards.
We help you to assess the ACS treatment industry and market's strengths, weaknesses, trends and revenue opportunities to 2021. You will see what the future holds.
Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Industry and market analysis to help your work - so you won't be left behind
Our report gives you revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from our survey. We include 78 tables and charts and a research interview (shown in the accompanying lists).
Acute Coronary Syndrome (ACS) Drug Market Prospects 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
- You will receive hard data for the acute coronary syndrome treatments industry and market - especially our revenue forecasts to 2021
- You will discover revenue predictions to 2021 for the overall ACS market and its components, seeing where the highest revenue growth will occur
- You will see the revenue prospects to 2021 for 12 leading drugs, with discussions of market potential and competition
- You will find ACS revenue predictions to 2021 for leading national markets (US, Japan, UK, Germany, France, Spain, Italy, China and India)
- You will learn how the ACS treatment industry will change from 2011 to 2021
- You will review the technologies in development, assessing potential among the R&D product candidates for ACS
- You will investigate competition and opportunities influencing the industry and market from 2011 onwards
- You will see what will stimulate and restrain the industry and market from 2011
- You will investigate commercial requirements - with therapeutic needs and sales opportunities discussed
- You will analyse opportunities and challenges for established companies and those seeking to enter the ACS market
- You will view opinions from our survey.
That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for cardiovascular drugs.
Order our report now to gain industry and market information you need
Our report can benefit everybody interested in the industry and market for treating acute coronary syndrome. We give predictions and answers you need. Don't miss out - please order our report now.
1. EXECUTIVE SUMMARY
1.1 Acute Coronary Syndrome (ACS) Treatment Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Scope of the Report
1.2.2 Chapter Outlines
1.3 Research and Analysis Methods
2. CARDIOVASCULAR DISEASES (CVD): OVERVIEW
2.1 Financial and Social Costs
2.2 Coronary Artery Disease (CAD)
2.3 Acute Coronary Syndrome (ACS)
2.3.1 Unstable Angina (UA)
2.3.2 Acute Myocardial Infarction (AMI)
2.3.2.1 NSTEMI/Non-Q-wave Myocardial Infarction
2.3.2.2 STEMI/Q-wave Myocardial Infarction
2.4 Most ACS Patients are UA/NSTEMI
2.5 Risk Factors
3. TREATMENT OF ACUTE CORONARY SYNDROME
3.1 Therapeutic Categories for ACS
3.2 Antiplatelet Drugs/Platelet Aggregation Inhibitors
3.2.1 ADP Receptor Antagonists/Thienopyridines
3.2.2 Glycoprotein Inhibitors
3.2.3 COX Inhibitors and Aspirin
3.3 Anticoagulants
3.3.1 Heparins
3.3.2 Vitamin K Antagonists and Warfarin
3.4 Fibrinolytics
3.4.1 Streptokinase and Urokinase
3.4.2 Tissue Plasminogen Activators (tPA)
3.4.3 Other Fibrinolytic Agents
3.5 Anti-Ischaemic Drugs
3.5.1 Nitrates
3.5.2 Beta-Blockers
3.6 Antihypertensives
3.7 Lipid-Lowering Treatments
4. ACS TREATMENT MARKET, 2010-2021
4.1 Scope and Limitations
4.2 The World ACS Treatment Market in 2010
4.3 The Platelet Aggregation Inhibitors Drug Class Dominates the World ACS Treatment Market
4.4 Plavix: The Leading ACS Drug in 2010
4.5 The Five Leading Drugs Accounted for over 70% of the World ACS Treatment Market in 2010
4.6 The World ACS Treatment Market, 2011-2021
4.6.1 Changing Market Shares of the Leading Therapeutic Classes
5. PLATELET AGGREGATION INHIBITORS MARKET, 2010-2021
5.1 Platelet Aggregation Inhibitors Market, 2010
5.2 Platelet Aggregation Inhibitors Market, 2011-2021
5.3 ADP Receptor Antagonists
5.3.1 Plavix (Clopidogrel): Maintaining its Market Leading Position
5.3.1.1 Generic Competition Due to Strike in the US ACS Market
5.3.1.2 Branded Competition: Marketed and in the Pipeline
5.3.1.3 Sales Forecast for Plavix in ACS, 2011-2021
5.3.2 Effient/Efient (Prasugrel), Daiichi Sankyo Company/Eli Lilly
5.3.2.1 Effient or Plavix?
5.3.2.2 Sales Forecast for Effient, 2011-2021
5.4 Glycoprotein IIb/IIIa Inhibitor
5.4.1 ReoPro (Abciximab), Eli Lilly/Centocor Ortho Biotech
5.4.1.1 Strong Competition from Integrilin
5.4.1.2 Market Presence of ReoPro Biosimilar
5.4.1.3 Sales Forecast for ReoPro, 2011-2021
5.4.2 Integrilin (Eptifibatide), Merck/GlaxoSmithKline (GSK)
5.4.2.1 Broader Indications Offering Advantage?
5.4.2.2 Sales Forecast for Integrilin, 2011-2021
5.5 COX Inhibitors
5.5.1 Aspirin Cardio, Bayer HealthCare Pharma
5.5.1.1 Aspirin Cardio Sales, 2010
5.5.1.2 Aspirin Cardio Sales Forecast, 2011-2021
5.5.1.3 OTC Treatment for the Prevention of Cardiovascular Disease?
5.6 The Future of Platelet Aggregation Inhibitors
6. ANTICOAGULANT TREATMENT MARKET, 2010-2021
6.1 Anticoagulant Treatment Market, 2010
6.2 Anticoagulants Treatment Market, 2011-2021
6.3 Injectable Anticoagulants
6.3.1 Lovenox/Clexane (Enoxaparin), Sanofi-Aventis
6.3.1.1 Lovenox is Approved for Multiple Indications: About 10% of its 2010 Sales Were from its Use in ACS
6.3.1.2 Competition for Lovenox
6.3.1.3 Sales Forecast for Lovenox, 2011-2021
6.3.2 Angiomax/Angiox (Bivalirudin), The Medicines Company
6.3.2.1 Strong Sales Performance in EU, 2010
6.3.2.2 Sales Forecast for Angiomax, 2011-2021
6.3.3 Arixtra (Fondaparinux), GSK
6.3.3.1 Arixtra Sales for Use in ACS Patients, 2010
6.3.3.2 Generic Competition for Arixtra
6.3.3.3 Sales Forecast for Arixtra, 2011-2021
6.4 Oral Anticoagulants
6.4.1 Coumadin (Warfarin), Bristol-Myers Squibb
6.4.1.1 Competition from Generics and Pipeline Drugs
6.4.1.2 Sales Forecast for Coumadin, 2011-2021
6.5 The Future of the Anticoagulants Market
7. FIBRINOLYTICS MARKET, 2010-2021
7.1 Fibrinolytics Market, 2010
7.2 Fibrinolytics Market, 2011-2021
7.3 Second-Generation Drug Metalyse/TNKase: Leading the Category
7.3.1 Mode of Administration May Give Metalyse the Edge
7.3.2 ASSENT Clinical Studies: A Mixed Message
7.3.3 Sales Forecast for Metalyse/TNKase, 2011-2021
7.4 Activase/Actilyse
7.4.1 Sales Forecast for Activase/Actilyse, 2011-2021
8. LEADING NATIONAL MARKETS FOR ACS DRUGS, 2010-2021
8.1 Leading National Markets in 2010
8.2 Leading National Markets: Sales Forecasts, 2011-2021
8.3 The US ACS Treatment Market, 2011-2021
8.4 Japanese ACS Treatment Market, 2011-2021
8.5 Leading ACS Treatment Markets in Europe, 2011-2021
8.6 Chinese ACS Treatment Market, 2011-2021
8.7 Indian ACS Treatment Market, 2011-2021
9. THE ACS DRUGS R&D PIPELINE
9.1 Pipeline Products in the ACS Treatment Industry
9.2 The Unmet Needs of the ACS Market have Encouraged R&D
9.3 Oral Anticoagulants in Development: Progress and Setbacks
9.3.1 Apixaban, Bristol-Myers Squibb/Pfizer
9.3.1.1 Filed for VTE, but Setback for Development in ACS Patients
9.3.2 Xarelto (Rivaroxaban), Bayer HealthCare Pharma/Johnson & Johnson Pharmaceutical Research & Development
9.3.3 Pradaxa (Dabigatran), Boehringer Ingelheim
9.3.4 TAK-442 (Letaxaban), Takeda Pharmaceuticals
9.4 Novel Parenteral Anticoagulants: Offering Advantages over the Current Standard of Care?
9.4.1 Otamixaban, Sanofi-Aventis
9.4.1.1 Rapid Onset of Action and Short Half-Life
9.4.2 REG1, Regado Biosciences
9.4.2.1 First Aptamer Drug for the Treatment of ACS
9.4.2.2 In Phase II Clinical Trials for ACS
9.5 Direct ADP Receptor Antagonists: Providing Rapid Onset and Offset of Action
9.5.1 Brilinta (Ticagrelor), AstraZeneca
9.5.1.1 Rejected for Reimbursement in France: Another Setback after Delay of Approval in the US
9.5.1.2 Factors Favouring Brilinta: A New Class of Drug
9.5.2 Elinogrel (PRT128), Novartis/Portola Pharmaceuticals
9.5.3 Cangrelor, The Medicines Company
9.6 Thrombin Receptor Antagonists: Novel Antiplatelet Drugs
9.6.1 Vorapaxar, Merck & Co.
9.6.1.1 Setback for a Promising Candidate
9.6.2 E555 (Atopaxar), Eisai
9.7 Other Drugs in Development for ACS
10. QUALITATIVE ANALYSIS OF THE INDUSTRY AND MARKET
10.1 Strengths and Weaknesses of the Sector
10.1.1 Increasing Prevalence of Disease Drives the Market
10.1.2 High Mortality Rates: Leading Cause of Death in Developed Countries
10.1.3 Available Treatments Have Been Successful in Reducing Mortality Rate
10.1.4 High Economic Cost of Disease
10.2 Opportunities and Threats
10.2.1 Developing Countries: Expanding New Markets
10.2.2 Managing Risk Factors and Opportunity for Growth of Drugs Used for Secondary Prevention
10.2.3 Novel Therapeutics Poised to Meet Needs in the Patient Population
10.2.4 Switching to OTC
10.2.5 The Threat of Generic Products
10.2.6 Termination of Late-Stage Clinical Trials
10.2.7 Downward Cost Pressures
10.2.8 A Buyer's Market?
10.2.9 Challenges to the Statin Drug Industry and Market
11. OPINION FROM OUR SURVEY
11.1 Interview with Dr Mauricio Cohen, Associate Professor of Medicine, University of Miami Miller School of Medicine; Director, Cardiac Catheterization Laboratory, University of Miami Hospital, US
11.1.1 Regado Biosciences' Lead Pipeline Anticoagulant Drug Candidate: REG1
11.1.2 Advantages Offered by the REG1 Anticoagulation System
11.1.3 Unmet Needs and Future of ACS Treatment Development
12. CONCLUSIONS
12.1 Principal Market Drivers
12.2 Principal Market Restraints
12.3 Driving Factors for the Success of Pipeline Drugs
12.4 Concluding Remarks on the Future of the Market
1.1 Acute Coronary Syndrome (ACS) Treatment Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Scope of the Report
1.2.2 Chapter Outlines
1.3 Research and Analysis Methods
2. CARDIOVASCULAR DISEASES (CVD): OVERVIEW
2.1 Financial and Social Costs
2.2 Coronary Artery Disease (CAD)
2.3 Acute Coronary Syndrome (ACS)
2.3.1 Unstable Angina (UA)
2.3.2 Acute Myocardial Infarction (AMI)
2.3.2.1 NSTEMI/Non-Q-wave Myocardial Infarction
2.3.2.2 STEMI/Q-wave Myocardial Infarction
2.4 Most ACS Patients are UA/NSTEMI
2.5 Risk Factors
3. TREATMENT OF ACUTE CORONARY SYNDROME
3.1 Therapeutic Categories for ACS
3.2 Antiplatelet Drugs/Platelet Aggregation Inhibitors
3.2.1 ADP Receptor Antagonists/Thienopyridines
3.2.2 Glycoprotein Inhibitors
3.2.3 COX Inhibitors and Aspirin
3.3 Anticoagulants
3.3.1 Heparins
3.3.2 Vitamin K Antagonists and Warfarin
3.4 Fibrinolytics
3.4.1 Streptokinase and Urokinase
3.4.2 Tissue Plasminogen Activators (tPA)
3.4.3 Other Fibrinolytic Agents
3.5 Anti-Ischaemic Drugs
3.5.1 Nitrates
3.5.2 Beta-Blockers
3.6 Antihypertensives
3.7 Lipid-Lowering Treatments
4. ACS TREATMENT MARKET, 2010-2021
4.1 Scope and Limitations
4.2 The World ACS Treatment Market in 2010
4.3 The Platelet Aggregation Inhibitors Drug Class Dominates the World ACS Treatment Market
4.4 Plavix: The Leading ACS Drug in 2010
4.5 The Five Leading Drugs Accounted for over 70% of the World ACS Treatment Market in 2010
4.6 The World ACS Treatment Market, 2011-2021
4.6.1 Changing Market Shares of the Leading Therapeutic Classes
5. PLATELET AGGREGATION INHIBITORS MARKET, 2010-2021
5.1 Platelet Aggregation Inhibitors Market, 2010
5.2 Platelet Aggregation Inhibitors Market, 2011-2021
5.3 ADP Receptor Antagonists
5.3.1 Plavix (Clopidogrel): Maintaining its Market Leading Position
5.3.1.1 Generic Competition Due to Strike in the US ACS Market
5.3.1.2 Branded Competition: Marketed and in the Pipeline
5.3.1.3 Sales Forecast for Plavix in ACS, 2011-2021
5.3.2 Effient/Efient (Prasugrel), Daiichi Sankyo Company/Eli Lilly
5.3.2.1 Effient or Plavix?
5.3.2.2 Sales Forecast for Effient, 2011-2021
5.4 Glycoprotein IIb/IIIa Inhibitor
5.4.1 ReoPro (Abciximab), Eli Lilly/Centocor Ortho Biotech
5.4.1.1 Strong Competition from Integrilin
5.4.1.2 Market Presence of ReoPro Biosimilar
5.4.1.3 Sales Forecast for ReoPro, 2011-2021
5.4.2 Integrilin (Eptifibatide), Merck/GlaxoSmithKline (GSK)
5.4.2.1 Broader Indications Offering Advantage?
5.4.2.2 Sales Forecast for Integrilin, 2011-2021
5.5 COX Inhibitors
5.5.1 Aspirin Cardio, Bayer HealthCare Pharma
5.5.1.1 Aspirin Cardio Sales, 2010
5.5.1.2 Aspirin Cardio Sales Forecast, 2011-2021
5.5.1.3 OTC Treatment for the Prevention of Cardiovascular Disease?
5.6 The Future of Platelet Aggregation Inhibitors
6. ANTICOAGULANT TREATMENT MARKET, 2010-2021
6.1 Anticoagulant Treatment Market, 2010
6.2 Anticoagulants Treatment Market, 2011-2021
6.3 Injectable Anticoagulants
6.3.1 Lovenox/Clexane (Enoxaparin), Sanofi-Aventis
6.3.1.1 Lovenox is Approved for Multiple Indications: About 10% of its 2010 Sales Were from its Use in ACS
6.3.1.2 Competition for Lovenox
6.3.1.3 Sales Forecast for Lovenox, 2011-2021
6.3.2 Angiomax/Angiox (Bivalirudin), The Medicines Company
6.3.2.1 Strong Sales Performance in EU, 2010
6.3.2.2 Sales Forecast for Angiomax, 2011-2021
6.3.3 Arixtra (Fondaparinux), GSK
6.3.3.1 Arixtra Sales for Use in ACS Patients, 2010
6.3.3.2 Generic Competition for Arixtra
6.3.3.3 Sales Forecast for Arixtra, 2011-2021
6.4 Oral Anticoagulants
6.4.1 Coumadin (Warfarin), Bristol-Myers Squibb
6.4.1.1 Competition from Generics and Pipeline Drugs
6.4.1.2 Sales Forecast for Coumadin, 2011-2021
6.5 The Future of the Anticoagulants Market
7. FIBRINOLYTICS MARKET, 2010-2021
7.1 Fibrinolytics Market, 2010
7.2 Fibrinolytics Market, 2011-2021
7.3 Second-Generation Drug Metalyse/TNKase: Leading the Category
7.3.1 Mode of Administration May Give Metalyse the Edge
7.3.2 ASSENT Clinical Studies: A Mixed Message
7.3.3 Sales Forecast for Metalyse/TNKase, 2011-2021
7.4 Activase/Actilyse
7.4.1 Sales Forecast for Activase/Actilyse, 2011-2021
8. LEADING NATIONAL MARKETS FOR ACS DRUGS, 2010-2021
8.1 Leading National Markets in 2010
8.2 Leading National Markets: Sales Forecasts, 2011-2021
8.3 The US ACS Treatment Market, 2011-2021
8.4 Japanese ACS Treatment Market, 2011-2021
8.5 Leading ACS Treatment Markets in Europe, 2011-2021
8.6 Chinese ACS Treatment Market, 2011-2021
8.7 Indian ACS Treatment Market, 2011-2021
9. THE ACS DRUGS R&D PIPELINE
9.1 Pipeline Products in the ACS Treatment Industry
9.2 The Unmet Needs of the ACS Market have Encouraged R&D
9.3 Oral Anticoagulants in Development: Progress and Setbacks
9.3.1 Apixaban, Bristol-Myers Squibb/Pfizer
9.3.1.1 Filed for VTE, but Setback for Development in ACS Patients
9.3.2 Xarelto (Rivaroxaban), Bayer HealthCare Pharma/Johnson & Johnson Pharmaceutical Research & Development
9.3.3 Pradaxa (Dabigatran), Boehringer Ingelheim
9.3.4 TAK-442 (Letaxaban), Takeda Pharmaceuticals
9.4 Novel Parenteral Anticoagulants: Offering Advantages over the Current Standard of Care?
9.4.1 Otamixaban, Sanofi-Aventis
9.4.1.1 Rapid Onset of Action and Short Half-Life
9.4.2 REG1, Regado Biosciences
9.4.2.1 First Aptamer Drug for the Treatment of ACS
9.4.2.2 In Phase II Clinical Trials for ACS
9.5 Direct ADP Receptor Antagonists: Providing Rapid Onset and Offset of Action
9.5.1 Brilinta (Ticagrelor), AstraZeneca
9.5.1.1 Rejected for Reimbursement in France: Another Setback after Delay of Approval in the US
9.5.1.2 Factors Favouring Brilinta: A New Class of Drug
9.5.2 Elinogrel (PRT128), Novartis/Portola Pharmaceuticals
9.5.3 Cangrelor, The Medicines Company
9.6 Thrombin Receptor Antagonists: Novel Antiplatelet Drugs
9.6.1 Vorapaxar, Merck & Co.
9.6.1.1 Setback for a Promising Candidate
9.6.2 E555 (Atopaxar), Eisai
9.7 Other Drugs in Development for ACS
10. QUALITATIVE ANALYSIS OF THE INDUSTRY AND MARKET
10.1 Strengths and Weaknesses of the Sector
10.1.1 Increasing Prevalence of Disease Drives the Market
10.1.2 High Mortality Rates: Leading Cause of Death in Developed Countries
10.1.3 Available Treatments Have Been Successful in Reducing Mortality Rate
10.1.4 High Economic Cost of Disease
10.2 Opportunities and Threats
10.2.1 Developing Countries: Expanding New Markets
10.2.2 Managing Risk Factors and Opportunity for Growth of Drugs Used for Secondary Prevention
10.2.3 Novel Therapeutics Poised to Meet Needs in the Patient Population
10.2.4 Switching to OTC
10.2.5 The Threat of Generic Products
10.2.6 Termination of Late-Stage Clinical Trials
10.2.7 Downward Cost Pressures
10.2.8 A Buyer's Market?
10.2.9 Challenges to the Statin Drug Industry and Market
11. OPINION FROM OUR SURVEY
11.1 Interview with Dr Mauricio Cohen, Associate Professor of Medicine, University of Miami Miller School of Medicine; Director, Cardiac Catheterization Laboratory, University of Miami Hospital, US
11.1.1 Regado Biosciences' Lead Pipeline Anticoagulant Drug Candidate: REG1
11.1.2 Advantages Offered by the REG1 Anticoagulation System
11.1.3 Unmet Needs and Future of ACS Treatment Development
12. CONCLUSIONS
12.1 Principal Market Drivers
12.2 Principal Market Restraints
12.3 Driving Factors for the Success of Pipeline Drugs
12.4 Concluding Remarks on the Future of the Market
LIST OF TABLES
Table 2.1 Hospital Admissions in the US Due to ACS, by Type of Condition, 2007
Table 4.1 List of ACS Drugs Recommended by ACC/AHA and ESC
Table 4.2 World ACS Treatment Market by Leading Therapeutic Classes ($m), 2010
Table 4.3 Leading Drugs in the World ACS Treatment Market ($m), 2010
Table 4.4 Plavix: Total Sales and Sales from ACS ($m), 2009 & 2010
Table 4.5 World ACS Treatment Market Forecast ($m), 2010-2021
Table 4.6 Market Shares (%) of Leading Therapeutic Classes in the ACS Treatment Market, 2010, 2015 & 2021
Table 5.1 Platelet Aggregation Inhibitors Market by Leading Products ($m), 2010
Table 5.2 Platelet Aggregation Inhibitors Market Sales Forecast ($m), 2010-2021
Table 5.3 List of Clopidogrel Generics Approved in the EU
Table 5.4 Plavix Sales Forecast ($m), 2010-2021
Table 5.5 Effient/Efient Sales Forecast ($m), 2010-2021
Table 5.6 ReoPro Sales Forecast ($m), 2010-2021
Table 5.7 Integrilin Sales Forecast ($m), 2010-2021
Table 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2021
Table 5.9 Market Shares (%) of the Leading Drugs in the Platelet Aggregation Inhibitors Market, 2010, 2015, & 2021
Table 6.1 Anticoagulant Drugs Market by Leading Products ($m), 2010
Table 6.2 Anticoagulants Market Sales Forecast ($m), 2010-2021
Table 6.3 Lovenox: Total Sales and Sales in ACS ($m), 2009 & 2010
Table 6.4 Lovenox Sales Forecast ($m), 2010-2021
Table 6.5 Angiomax/Angiox Sales ($m) by Region, 2009 & 2010
Table 6.6 Angiomax/Angiox Sales Forecast ($m), 2010-2021
Table 6.7 Arixtra Sales ($m) by Region, 2009 & 2010
Table 6.8 Arixtra Sales Forecast ($m), 2010-2021
Table 6.9 Coumadin Sales Forecast ($m), 2010-2021
Table 6.10 Market Shares (%) of the Leading Drugs in the Anticoagulants Market, 2010, 2015 & 2021
Table 7.1 Fibrinolytics Drugs Market by Leading Products ($m), 2010
Table 7.2 Fibrinolytics Market Sales Forecast ($m), 2010-2021
Table 7.3 Metalyse/TNKase Sales Forecast ($m), 2010-2021
Table 7.4 Activase/Actilyse Sales Forecast ($m), 2010-2021
Table 8.1 Leading National Markets for ACS Drugs ($m), 2010
Table 8.2 Leading National Markets for ACS Drugs: Forecasts ($m), 2010-2021
Table 8.3 Leading National Markets: Market Shares (%), 2010, 2015 & 2021
Table 9.1 Key Pipeline Products for the Treatment of ACS, 2011
Table 9.2 Comparison of Marketed and Pipeline Oral Anticoagulants, 2011
Table 9.3 Comparison of Marketed and Pipeline Parenteral Anticoagulant Drugs, 2011
Table 9.4 Comparison of Marketed and Pipeline ADP Receptor Antagonist Drugs, 2011
Table 10.1 SWOT Analysis of the World ACS Treatment Industry and Market, 2011
Table 10.2 Patent Expiries of Some Marketed ACS Drugs
Table 2.1 Hospital Admissions in the US Due to ACS, by Type of Condition, 2007
Table 4.1 List of ACS Drugs Recommended by ACC/AHA and ESC
Table 4.2 World ACS Treatment Market by Leading Therapeutic Classes ($m), 2010
Table 4.3 Leading Drugs in the World ACS Treatment Market ($m), 2010
Table 4.4 Plavix: Total Sales and Sales from ACS ($m), 2009 & 2010
Table 4.5 World ACS Treatment Market Forecast ($m), 2010-2021
Table 4.6 Market Shares (%) of Leading Therapeutic Classes in the ACS Treatment Market, 2010, 2015 & 2021
Table 5.1 Platelet Aggregation Inhibitors Market by Leading Products ($m), 2010
Table 5.2 Platelet Aggregation Inhibitors Market Sales Forecast ($m), 2010-2021
Table 5.3 List of Clopidogrel Generics Approved in the EU
Table 5.4 Plavix Sales Forecast ($m), 2010-2021
Table 5.5 Effient/Efient Sales Forecast ($m), 2010-2021
Table 5.6 ReoPro Sales Forecast ($m), 2010-2021
Table 5.7 Integrilin Sales Forecast ($m), 2010-2021
Table 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2021
Table 5.9 Market Shares (%) of the Leading Drugs in the Platelet Aggregation Inhibitors Market, 2010, 2015, & 2021
Table 6.1 Anticoagulant Drugs Market by Leading Products ($m), 2010
Table 6.2 Anticoagulants Market Sales Forecast ($m), 2010-2021
Table 6.3 Lovenox: Total Sales and Sales in ACS ($m), 2009 & 2010
Table 6.4 Lovenox Sales Forecast ($m), 2010-2021
Table 6.5 Angiomax/Angiox Sales ($m) by Region, 2009 & 2010
Table 6.6 Angiomax/Angiox Sales Forecast ($m), 2010-2021
Table 6.7 Arixtra Sales ($m) by Region, 2009 & 2010
Table 6.8 Arixtra Sales Forecast ($m), 2010-2021
Table 6.9 Coumadin Sales Forecast ($m), 2010-2021
Table 6.10 Market Shares (%) of the Leading Drugs in the Anticoagulants Market, 2010, 2015 & 2021
Table 7.1 Fibrinolytics Drugs Market by Leading Products ($m), 2010
Table 7.2 Fibrinolytics Market Sales Forecast ($m), 2010-2021
Table 7.3 Metalyse/TNKase Sales Forecast ($m), 2010-2021
Table 7.4 Activase/Actilyse Sales Forecast ($m), 2010-2021
Table 8.1 Leading National Markets for ACS Drugs ($m), 2010
Table 8.2 Leading National Markets for ACS Drugs: Forecasts ($m), 2010-2021
Table 8.3 Leading National Markets: Market Shares (%), 2010, 2015 & 2021
Table 9.1 Key Pipeline Products for the Treatment of ACS, 2011
Table 9.2 Comparison of Marketed and Pipeline Oral Anticoagulants, 2011
Table 9.3 Comparison of Marketed and Pipeline Parenteral Anticoagulant Drugs, 2011
Table 9.4 Comparison of Marketed and Pipeline ADP Receptor Antagonist Drugs, 2011
Table 10.1 SWOT Analysis of the World ACS Treatment Industry and Market, 2011
Table 10.2 Patent Expiries of Some Marketed ACS Drugs
LIST OF FIGURES
Figure 2.1 Clinical Conditions Grouped Under ACS
Figure 2.2 Classification of ACS Conditions
Figure 2.3 Shares (%) of Hospital Admissions in the US by Type of Condition, 2007
Figure 3.1 Treatment for ACS: Mechanical and Pharmacological Therapy, 2011
Figure 3.2 Use of Drug Therapy for ACS Treatment, 2011
Figure 4.1 World ACS Treatment Market Shares (%) by Leading Therapeutic Classes, 2010
Figure 4.2 Sales ($m) of Leading Drugs in the World ACS Treatment Market, 2010
Figure 4.3 World ACS Treatment Market Forecasts ($m), 2010-2021
Figure 4.4 Forecasts ($m) for Leading Therapeutic Classes of the ACS Treatment Market, 2010-2021
Figure 4.5 World ACS Treatment Market Shares (%) by Leading Therapeutic Classes, 2015
Figure 4.6 World ACS Treatment Market Shares (%) by Leading Therapeutic Classes, 2021
Figure 5.1 Market Shares (%) of Leading Platelet Aggregation Inhibitors, 2010
Figure 5.2 Platelet Aggregation Inhibitors Market: Sales Forecast ($m), 2010-2021
Figure 5.3 Plavix Sales Forecast ($m), 2010-2021
Figure 5.4 Effient/Efient Sales Forecast ($m), 2010-2021
Figure 5.5 ReoPro Sales Forecast ($m), 2010-2021
Figure 5.6 Integrilin Sales Forecast ($m), 2010-2021
Figure 5.7 Aspirin Cardio Sales Forecast ($m), 2010-2021
Figure 5.8 Market Shares (%) of Leading Platelet Aggregation Inhibitors, 2015
Figure 5.9 Market Shares (%) of Leading Platelet Aggregation Inhibitors, 2021
Figure 6.1 Market Shares (%) of Leading Anticoagulant Drugs, 2010
Figure 6.2 Anticoagulants Market Sales Forecast ($m), 2010-2021
Figure 6.3 Lovenox Sales Forecast ($m), 2010-2021
Figure 6.4 Angiomax/Angiox Sales Forecast ($m), 2010-2021
Figure 6.5 Arixtra Sales Forecast ($m), 2010-2021
Figure 6.6 Coumadin Sales Forecast ($m), 2010-2021
Figure 6.7 Market Shares (%) of Leading Anticoagulants, 2015
Figure 6.8 Market Shares (%) of Leading Anticoagulants, 2021
Figure 7.1 Market Shares (%) of Leading Fibrinolytic Drugs, 2010
Figure 7.2 Fibrinolytics Market Sales Forecast ($m), 2010-2021
Figure 7.3 Metalyse/TNKase Sales Forecast ($m), 2010-2021
Figure 7.4 Activase/Actilyse Sales Forecast ($m), 2010-2021
Figure 8.1 ACS Treatment Market Shares (%) by Country, 2010
Figure 8.2 ACS Treatment Market Shares (%) by Country, 2015
Figure 8.3 ACS Treatment Market Shares (%) by Country, 2021
Figure 8.4 The US ACS Treatment Market Forecast ($m), 2010-2021
Figure 8.5 The Japanese ACS Treatment Market Forecast ($m), 2010-2021
Figure 8.6 ACS Treatment Market Forecasts for Leading European Countries ($m), 2010-2021
Figure 8.7 Indian and Chinese ACS Treatment Market Forecasts ($m), 2010-2021
COMPANIES LISTED
Abbott Laboratories
Ablynx
Acino Pharma
Alchemia
American College of Cardiology (ACC)
American Heart Association (AHA)
Amphastar Pharmaceuticals
Anthera Pharmaceuticals
Apicore
Apotex
APP Pharmaceuticals
Astellas Pharma
AstraZeneca
Barr Pharmaceuticals
Bayer HealthCare Pharma
Bharat Biotech International
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
British Heart Foundation
Centocor Ortho Biotech
Cerenis Therapeutics
Cobalt Pharmaceuticals Company
COR Therapeutics
Corimmun GmbH
CSL Behring
Daiichi Sankyo
Dr. Reddy's Laboratories
Eisai
EKR Therapeutics
Eli Lilly
European Commission (EC)
European Medicines Agency (EMA)
European Society for Cardio-Thoracic Surgery (EACTS)
European Society of Cardiology (ESC)
Food and Drug Administration (US FDA)
French Transparency Commission
Fresenius Kabi Group
Genentech
Genzyme Corporation
GlaxoSmithKline
HCS bvba
Hoffmann-La Roche
Hospira
Iroko Cardio International
ISU Abxis
Johnson & Johnson
Korean FDA
KRKA
Kyowa Hakko Kirin
Medicure
Merck & Co.
Millennium Pharmaceuticals
Mitsubishi Kasei
Momenta Pharmaceuticals
Mylan
Novartis
Pfizer
Portola Pharmaceuticals
Procorde GmbH
QualiMed
Regado Biosciences
Roche
Sandoz
Sanofi-Aventis
Sanofi-Synthelabo
Schering-Plough
Society for Cardiovascular Angiography and Interventions (SCAI)
Sun Pharmaceutical Industries
Tad Pharma
Takeda Pharmaceuticals Company
Taro Pharmaceutical Industries
Teva Pharmaceutical Industries
The Arrow Group
The Medicines Company
Trigen GmbH
U.S. Patent and Trademark Office (USPTO)
VIA Pharmaceuticals
Viron Therapeutics
Watson Pharmaceuticals
Figure 2.1 Clinical Conditions Grouped Under ACS
Figure 2.2 Classification of ACS Conditions
Figure 2.3 Shares (%) of Hospital Admissions in the US by Type of Condition, 2007
Figure 3.1 Treatment for ACS: Mechanical and Pharmacological Therapy, 2011
Figure 3.2 Use of Drug Therapy for ACS Treatment, 2011
Figure 4.1 World ACS Treatment Market Shares (%) by Leading Therapeutic Classes, 2010
Figure 4.2 Sales ($m) of Leading Drugs in the World ACS Treatment Market, 2010
Figure 4.3 World ACS Treatment Market Forecasts ($m), 2010-2021
Figure 4.4 Forecasts ($m) for Leading Therapeutic Classes of the ACS Treatment Market, 2010-2021
Figure 4.5 World ACS Treatment Market Shares (%) by Leading Therapeutic Classes, 2015
Figure 4.6 World ACS Treatment Market Shares (%) by Leading Therapeutic Classes, 2021
Figure 5.1 Market Shares (%) of Leading Platelet Aggregation Inhibitors, 2010
Figure 5.2 Platelet Aggregation Inhibitors Market: Sales Forecast ($m), 2010-2021
Figure 5.3 Plavix Sales Forecast ($m), 2010-2021
Figure 5.4 Effient/Efient Sales Forecast ($m), 2010-2021
Figure 5.5 ReoPro Sales Forecast ($m), 2010-2021
Figure 5.6 Integrilin Sales Forecast ($m), 2010-2021
Figure 5.7 Aspirin Cardio Sales Forecast ($m), 2010-2021
Figure 5.8 Market Shares (%) of Leading Platelet Aggregation Inhibitors, 2015
Figure 5.9 Market Shares (%) of Leading Platelet Aggregation Inhibitors, 2021
Figure 6.1 Market Shares (%) of Leading Anticoagulant Drugs, 2010
Figure 6.2 Anticoagulants Market Sales Forecast ($m), 2010-2021
Figure 6.3 Lovenox Sales Forecast ($m), 2010-2021
Figure 6.4 Angiomax/Angiox Sales Forecast ($m), 2010-2021
Figure 6.5 Arixtra Sales Forecast ($m), 2010-2021
Figure 6.6 Coumadin Sales Forecast ($m), 2010-2021
Figure 6.7 Market Shares (%) of Leading Anticoagulants, 2015
Figure 6.8 Market Shares (%) of Leading Anticoagulants, 2021
Figure 7.1 Market Shares (%) of Leading Fibrinolytic Drugs, 2010
Figure 7.2 Fibrinolytics Market Sales Forecast ($m), 2010-2021
Figure 7.3 Metalyse/TNKase Sales Forecast ($m), 2010-2021
Figure 7.4 Activase/Actilyse Sales Forecast ($m), 2010-2021
Figure 8.1 ACS Treatment Market Shares (%) by Country, 2010
Figure 8.2 ACS Treatment Market Shares (%) by Country, 2015
Figure 8.3 ACS Treatment Market Shares (%) by Country, 2021
Figure 8.4 The US ACS Treatment Market Forecast ($m), 2010-2021
Figure 8.5 The Japanese ACS Treatment Market Forecast ($m), 2010-2021
Figure 8.6 ACS Treatment Market Forecasts for Leading European Countries ($m), 2010-2021
Figure 8.7 Indian and Chinese ACS Treatment Market Forecasts ($m), 2010-2021
COMPANIES LISTED
Abbott Laboratories
Ablynx
Acino Pharma
Alchemia
American College of Cardiology (ACC)
American Heart Association (AHA)
Amphastar Pharmaceuticals
Anthera Pharmaceuticals
Apicore
Apotex
APP Pharmaceuticals
Astellas Pharma
AstraZeneca
Barr Pharmaceuticals
Bayer HealthCare Pharma
Bharat Biotech International
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
British Heart Foundation
Centocor Ortho Biotech
Cerenis Therapeutics
Cobalt Pharmaceuticals Company
COR Therapeutics
Corimmun GmbH
CSL Behring
Daiichi Sankyo
Dr. Reddy's Laboratories
Eisai
EKR Therapeutics
Eli Lilly
European Commission (EC)
European Medicines Agency (EMA)
European Society for Cardio-Thoracic Surgery (EACTS)
European Society of Cardiology (ESC)
Food and Drug Administration (US FDA)
French Transparency Commission
Fresenius Kabi Group
Genentech
Genzyme Corporation
GlaxoSmithKline
HCS bvba
Hoffmann-La Roche
Hospira
Iroko Cardio International
ISU Abxis
Johnson & Johnson
Korean FDA
KRKA
Kyowa Hakko Kirin
Medicure
Merck & Co.
Millennium Pharmaceuticals
Mitsubishi Kasei
Momenta Pharmaceuticals
Mylan
Novartis
Pfizer
Portola Pharmaceuticals
Procorde GmbH
QualiMed
Regado Biosciences
Roche
Sandoz
Sanofi-Aventis
Sanofi-Synthelabo
Schering-Plough
Society for Cardiovascular Angiography and Interventions (SCAI)
Sun Pharmaceutical Industries
Tad Pharma
Takeda Pharmaceuticals Company
Taro Pharmaceutical Industries
Teva Pharmaceutical Industries
The Arrow Group
The Medicines Company
Trigen GmbH
U.S. Patent and Trademark Office (USPTO)
VIA Pharmaceuticals
Viron Therapeutics
Watson Pharmaceuticals
